冠状动脉粥样硬化的细胞与分子影像:临床应用
该综述指出冠心病发病率再度上升,基于结构影像的进展加深了对动脉粥样硬化发病机制的理解;分子影像使构成粥样硬化病理生物学的分子与细胞得以临床可视化。整合分子与解剖指标有助于理解疾病进展、个体化风险及药物与器械疗效,炎症细胞与分子影像有望开启风险评估和个体化治疗的新时代。
要点
- 分子影像可临床可视化驱动动脉粥样硬化的分子与细胞。
- 整合分子与解剖影像加深对疾病进展和个体化风险的理解。
- 炎症等疾病活动的细胞分子影像有望用于风险评估与个体化治疗。
核心结论
- 细胞与分子影像整合解剖学指标,可加深对动脉粥样硬化疾病进展、患者个体化风险及药物与器械疗效的理解。
研究设计与样本
- 综述,总结冠状动脉疾病细胞与分子影像的最新进展,并提供近期转化与临床应用的路线图。
主要发现
- 逆转了1990年代至2010年代初期取得的初步成效后,冠状动脉疾病发病率目前正在上升,并且在世界许多地区构成主要死因。
- 近年来,无创与有创的、基于结构的影像技术取得实质性进展,可 delineate 粥样斑块负荷和解剖组成,增进了对动脉粥样硬化发病机制的理解。
- 影像剂与硬件技术的进步推动了分子影像这一新兴领域,使构成动脉粥样硬化病理生物学的分子和细胞得以临床可视化。
- 对炎症作为冠状动脉疾病患者不良结局残余风险标志物的高度认识,使炎症及其他疾病活动的细胞与分子影像有望开启风险评估和个体化医疗与介入治疗的新时代。
- 分子影像有望评估干预措施对致动脉粥样硬化过程的作用、在体内验证效应,并可能为最佳剂量选择和疗程提供信息。
临床怎么用
- 将分子影像与解剖影像整合,用于深入理解动脉粥样硬化疾病进展和患者个体化风险。
- 利用炎症等疾病活动的细胞与分子影像辅助风险评估,并支持个体化药物与介入治疗决策。
- 分子影像可用于在体内评估干预措施对致动脉粥样硬化过程的作用,并可能为剂量选择和疗程提供信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Reversing initial gains realized in the 1990s-2010s, coronary artery disease rates are now increasing and represent the dominant cause of death in many parts of the world. In recent years, substantive advances in non-invasive and invasive structural-based imaging techniques that delineate atheroma burden and anatomical composition have increased understanding of the pathogenesis of atherosclerosis. Driven by advances in imaging agent and hardware technology, the burgeoning field of molecular imaging has enabled clinical visualization of molecules and cells that underpin atherosclerosis pathobiology. Integrating the molecular and anatomical measures of atherosclerosis has promoted a deeper understanding of disease progression, patient-specific risk, and the effects of atherosclerosis pharmacotherapeutics and devices. With the great recognition of the role of inflammation as a residual risk marker of adverse outcomes for coronary artery disease patients, cellular and molecular imaging of inflammation and other disease activities is positioned to usher in a new era of risk assessment and personalized medical and interventional therapeutics for atherosclerosis patients. Moreover, molecular imaging offers the potential for assessing the actions of interventions on atherogenic processes, validating effects in vivo, and possibly informing optimal dose selection and treatment duration. This review will present the state-of-the-art in coronary artery disease cellular and molecular imaging and provide a roadmap for near-term translational and clinical applications.
引用
- Jaffer FA, Dweck MR, Tearney GJ, et al. Cellular and molecular imaging of coronary atherosclerosis: clinical applications. Eur Heart J. 2025. PMID: 41222955. doi:10.1093/eurheartj/ehaf804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。